# psoriasis - glm-5.2

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4460
- Completion tokens: 3367
- Reasoning tokens: 
- Total tokens: 7827
- API requests reported: 
- Elapsed seconds: 227.394
- Final benchmark system: raw; file rank 3/5; original repeat 4; model vendor: Zhipu AI

---
Based on the provided transcriptomic data comparing psoriatic lesional skin to normal control skin, I offer the following multidimensional, evidence-grounded, and biologically verifiable interpretation of the results.

### 1. Overall Biological Interpretation

The transcriptomic profile of the psoriatic lesional skin is heavily dominated by a massive disruption of epidermal homeostasis, characterized by hyperproliferation, aberrant differentiation, and a robust antimicrobial and inflammatory response. The data clearly recapitulates the classic pathophysiological loop of psoriasis: keratinocyte stress triggers innate immune signaling (specifically IL-36 and IL-17/TNF-axis cytokines), which in turn drives hyperproliferation and impaired terminal differentiation of the epidermis. This altered tissue microenvironment is further defined by the recruitment of neutrophils and adaptive immune cells, alterations in tissue metabolism (e.g., polyamine and lipid synthesis), and reactivation of epidermal stem cell-like programs. Overall, the signals point toward a highly active, inflamed tissue state with a pronounced distortion of the keratinocyte differentiation trajectory.

### 2. Core Biological Programs

**1. IL-36 / IL-17-TNF Inflammatory Amplification Loop**
*   **Direction or prognostic association:** Upregulated (Disease-state)
*   **Major supporting genes:** *IL36A, IL36G, IL36RN, IL19, IL20, IL26, TNIP3, IRAK2*
*   **Standardized pathway:** Hallmark: Inflammatory Response; KEGG: Cytokine-cytokine receptor interaction; Reactome: Signaling by Interleukins
*   **Explanation:** The presence of both *IL36A*/*IL36G* (agonists) and *IL36RN* (antagonist) alongside *IL19*, *IL20*, and *IL26* strongly indicates activation of the IL-36 signaling axis, a known driver of psoriatic inflammation that acts upstream of IL-17 and TNF. *TNIP3* and *IRAK2* further support this, as they are regulators/signal transducers in Toll/IL-1 receptor signaling cascades, acting to amplify the downstream NF-kB response.
*   **Strength of evidence and limitations:** The evidence is exceptionally strong due to the highly coordinated upregulation of multiple ligands and regulators within the same cytokine family. A limitation is that the input data cannot distinguish whether these cytokines are produced by keratinocytes, immune cells, or both; though in psoriasis, keratinocytes are a primary source of IL-36 and IL-20 subfamily cytokines.

**2. Aberrant Keratinocyte Differentiation (Hyperproliferative & Cornification Program)**
*   **Direction or prognostic association:** Upregulated (Disease-state)
*   **Major supporting genes:** *SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2G, SPRR3, LCE3A, LCE3D, SERPINB3, SERPINB4, SERPINB11, KRT6A, GJB2*
*   **Standardized pathway:** GO: Epidermis development; GO: Peptide cross-linking via Lanthionine; KEGG: EGFR tyrosine kinase inhibitor resistance
*   **Explanation:** The coordinated massive upregulation of Small Proline-Rich Proteins (SPRRs), Late Cornified Envelope (LCEs), SerpinB family members, and keratin 6A strongly indicates disturbed cornification and epidermal barrier formation. These genes are cross-linking components of the cornified envelope (CE). In psoriasis, these are aberrantly expressed as the tissue attempts to rapidly produce a thicker stratum corneum in response to stress, resulting in parakeratosis and impaired barrier function (notable via KRT6A induction, characteristic of psoriatic hyperproliferation).
*   **Strength of evidence and limitations:** High strength, as these classic biomarkers of psoriatic epidermal remodeling are highly significant and coordinated. Yet, since lesional skin is structurally altered, it remains difficult to differentiate if this signal reflects true functional pathway dysregulation or simply a massive shift in the proportional cell-type composition toward immature keratinocytes.

**3. Innate Antimicrobial & Neutrophil Defense Response**
*   **Direction or prognostic association:** Upregulated (Disease-state)
*   **Major supporting genes:** *S100A12, S100A7, S100A7A, S100A8, DEFB4A, DEFB4B, DEFB103A/B, PI3, CXCL13, CXCR2*
*   **Standardized pathway:** Hallmark: TNFα signaling via NF-kB; GO: Neutrophil-mediated immunity
*   **Explanation:** The *S100A* family (alarmins) and beta-defensins are classic innate antimicrobial peptides upregulated in psoriatic epidermis. The presence of myeloid cell attractants like *CXCL13* (B/T cell attractant) and CXCR2 ligands indicates active leukocyte recruitment. Together, these map to the amplified immune surveillance and defensive mechanisms characteristic of psoriatic lesions.
*   **Strength of evidence and limitations:** Very strong evidence. However, the difficulty lies in distinguishing the proportional contribution of increased neutrophilic infiltration (Munro's microabscesses in psoriasis) as opposed to keratinocyte immune reprogramming, since both cell types express these antimicrobial peptides.

**4. Alteration in Tissue Metabolism / Xenobiotic Response**
*   **Direction or prognostic association:** Upregulated (Disease-state)
*   **Major supporting genes:** *KYNU, AKR1B10, AKR1B15, PLA2G4D, PLA2G4E, FABP5*
*   **Standardized pathway:** KEGG: Tryptophan metabolism; Reactome: Metabolism of lipids
*   **Explanation:** The presence of *KYNU* (kynureninase) indicates enhanced catabolism of tryptophan, which is critical for sustaining T-cell responses and is known to be elevated in psoriasis. Meanwhile, *AKR1B10/15*, *FABP5*, and *PLA2G4D/E* highlight major shifts in lipid metabolism and eicosanoid/prostaglandin synthesis, which are necessary membrane and signaling precursors for this highly active, rapidly dividing tissue. 
*   **Strength of evidence and limitations:** Moderate to high evidence. The specific functional directionality (e.g., toward immunosuppressive or pro-inflammatory metabolites) cannot be inferred from transcriptomic data alone and requires metabolomic confirmation.

### 3. Key Genes and Interaction Modules

1.  **IL36A / IL36G / IL36RN / IL20 / IL19 / IL26 Module**
    *   **Statistical Direction:** All strongly upregulated (*IL36A* log2FC 11.37, *IL36G* log2FC 5.68).
    *   **Potential Role:** Key initiator and amplifier of local cytokine networks.
    *   **Nature of proposed relationship: Pathway co-membership and Regulatory interaction** (putative direct binding synergies ommitted as direct protein binding is not confirmed here). They act synergistically to activate their shared receptor complexes, triggering downstream cascades. Literature evidence supports a regulatory loop where IL-36 drives IL-19/20 expression.

2.  **IL36 -> TNIP3 / IRAK2 -> NF-kB Signaling Axis**
    *   **Statistical Direction:** Upregulated.
    *   **Potential Role:** Receptor-proximal signaling transduction.
    *   **Nature of proposed relationship: Pathway co-membership; Indirect regulatory relationship**. *TNIP3* (a negative regulator of NF-kB) and *IRAK2* (a kinase in the Toll/IL-1R pathway) act as message relay proteins downstream of *IL36* receptor activation. They do not directly bind the cytokines but are transcriptionally co-regulated as part of the feedback loop.

3.  **IL-17-induced Hyperproliferation Axis (*KRT6A* & *SPRR* cluster)**
    *   **Statistical Direction:** Upregulated.
    *   **Potential Role:** Epidermal remodeling and structural integrity compromise.
    *   **Nature of proposed relationship: Co-expression; Indirect_putative relationship**. It has been established in the literature that IL-17 and TNF secreted by local T-cells and neutrophils drive the expression of *KRT6A* and *SPRR* family genes in keratinocytes. Thus, there is an indirect regulatory relationship where the inflammatory milieu dictates structural protein expression.

4.  **S100A7/12 Antimicrobial Cluster**
    *   **Statistical Direction:** Extremely highly upregulated (*S100A12* log2FC 8.33).
    *   **Potential Role:** Amplification of local inflammation (alarmin signaling).
    *   **Nature of proposed relationship: Co-expression**. Both genes display similar expression profiles and functions, acting through similar innate receptors like RAGE. No direct physical interaction among these exact isoforms is claimed by the data.

### 4. Validation Priorities

**1. Mechanistic hypothesis: Role of IL-36 Ligands in Psoriasis Severity**
*   **Priority Rationale:** The IL-36 module is massively upregulated and serves as a known upstream "driver" of psoriatic inflammation.
*   **Evidence:** *IL36A/G* expression is significantly elevated (*IL36A* log2FC 11.37, *IL36RN* log2FC 3.00). Current data suggests robust axis activation.
*   **External Evidence:** IL-36 is established in literature as a key psoriasis driver; biological agents targeting this pathway are already developed (e.g., Spesolimab) and clinically approved for generalized pustular psoriasis, confirming established evidence for general psoriasis but leaving plaque-type mechanistic dependencies as a supported hypothesis.
*   **Next Step:** Spatial transcriptomics on separate lesional and non-lesional biopsies to identify if IL36A expressing cells are keratinocytes or stromal cells in plaque psoriasis.

**2. Therapeutic target: EGFR and Cornification Inhibitors**
*   **Priority Rationale:** The massive upregulation of *SPRR*, *SERPINB*, and *PI3* indicates a tissue urgently attempting barrier repair but producing a malformed, hyper-thickened stratum corneum instead.
*   **Evidence:** Highly significant, large fold changes for multiple structural genes.
*   **External Evidence:** EGFR inhibition by *SPRR* and *PI3* is literature-supported. EGFR inhibitors are not routinely causal therapeutic targets for psoriasis, but localized blockade of these specific keratinocyte responses could be adjunct therapy.
*   **Classification:** Mechanistic/Supported hypothesis.

**3. Biomarker: Assessment of IL-36 Signaling Blockade Efficacy**
*   **Priority Rationale:** *IL36A/G/RN* expression combined could serve as a biomarker predicting response to specific anti-cytokine therapies.
*   **Evidence:** Easily detectable and highly significant in the current dataset.
*   **Classification:** Supported hypothesis.

**4. Interaction / network hypothesis: IL-17/IL-36 Regulatory Crosstalk**
*   **Priority Rationale:** Whether IL-36 acts upstream or in a positive feedback loop with IL-17 and TNF is relevant to understanding pathogenesis.
*   **Evidence:** The input dataset confirms simultaneous upregulation of both *IL36A/G* and *TNIP3* (TNF signaling regulator).
*   **Classification:** Supported hypothesis.

**5. Confounding or composition check: Immune cell deconvolution**
*   **Priority Rationale:** To determine whether the "inflammation program" findings represent true parenchymal tissue inflammation or simply variation due to differential leukocyte content.
*   **Next Step:** Use computational deconvolution tools (e.g., CIBERSORTx) or flow cytometry on fresh lesional samples to quantify proportions of specific cell types.

### 5. Evidence Grounding

**For Primary Programs 1 (Inflammation) and 2 (Differentiation)**
*   **Direct evidence from the input dataset:** Very strong. Multiple genes (*IL36A, IL36G, SPRR2A, KRT6A, S100A12*) are heavily significantly upregulated (p < 10^-80).
*   **Pathway / ontology evidence:** Strong. Genes map cleanly to established Hallmark/KEGG pathways (IL signaling, epidermal development).
*   **Protein interaction or regulatory evidence:** Sufficient. The existence of antagonists (*IL36RN*) supports complex, tight regulatory action in these modules.
*   **Disease-association and published literature evidence:** Strong external evidence confirming these processes as classic hallmarks of psoriasis.
*   **Integration:** These sources are genuinely independent; pattern matching in transcriptomes aligns with known receptor-ligand biology independently mapped out in earlier molecular studies.

**For Primary Programs 3 (Metabolism) and 4 (Defense)**
*   **Direct evidence from the input dataset:** Moderate to strong (*KYNU, PLA2G4D*).
*   **Expression or tissue-specific evidence:** Well-established. However, conflicting evidence may appear regarding cell-type origin (keratinocytes vs infiltrating neutrophils).
*   **Insufficient evidence:** The data alone does not provide direct protein-protein interaction evidence for these modules, making purely mechanistic causal conclusions limited.

### 6. Limitations and Alternative Explanations

1.  **Tissue or cell-composition differences (Most Critical Limitation)**
    The upregulation of *CXCL13* and *CXCR2* may simply reflect an increase in leukocyte populations rather than a transcriptional shift within epidermal cells. Similarly, *S100A* and *DEFB4A/B* may be elevated due to neutrophil accumulation and abscess formation rather than keratinocyte expression. Normalizing this is difficult without single-cell RNA-sequencing or immunohistochemistry to establish expression at the individual cell-type level.
2.  **Broad or nonspecific pathway enrichment**
    The *"Inflammatory Response"* pathway driven by *S100A* genes is upregulated in many infectious and autoimmune processes. The presence of these genes is not exclusively specific to psoriasis but rather reflects a generic inflamed epidermal state. Differentiating a psoriasis-specific from a general "wound/injury" response requires comparison with other benign inflammatory dermatoses.
3.  **Disease severity and Treatment Exposure**
    The input metadata does not include details on prior systemic treatment. A patient heavily exposed to systemic immunosuppressants or biologics may have altered immune profiles affecting 'classic inflammatory gene' outputs compared to bio-naïve severe psoriasis cases.
4.  **Association-versus-causation Ambiguity**
    Observing that *IL36A* and *SPRR2A* are co-upregulated does not inherently show that the inflammatory axis causes the epidermal hyperplasia or vice versa, although biological literature supports directional signaling.
5.  **Tumor purity / Epidermal-to-Dermis ratio**
    Psoriasis features profound epidermal acanthosis (thickening). The ratio of epidermis to dermis in lesional biopsies is skewed. Thus, normalizing to "healthy skin" controls where epidermis is thinner may exaggerate fold changes in keratinocyte genes like *KRT6A* and *SPRR2A*. This can be investigated by micro-dissection before RNA extraction or scRNA-seq analysis.
